Dr. Martens (LON:DOCS) Shares Down 11.6% – Should You Sell?

Dr. Martens plc (LON:DOCS)’s stock price fell 11.6% on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. 9,032,986 shares changed hands during mid-day trading, an increase of 342% from the average session volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Analyst Ratings Changes

DOCS has been the topic of several analyst reports. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Tuesday. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Dr. Martens has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Up 3.6%

The firm’s 50 day simple moving average is GBX 75.76 and its 200-day simple moving average is GBX 83.16. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The stock has a market capitalization of £657.97 million, a price-to-earnings ratio of 40.04, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Equities analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson purchased 96,000 shares of the stock in a transaction on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, with a total value of £75,840. Over the last quarter, insiders purchased 97,130 shares of company stock worth $7,673,816. 2.79% of the stock is owned by insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.